857904-20-2

Basic information

• Product Name: CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester;Tert-butyl (1S,2S)-1-benzyl-2-hydroxy-3-{1-[4-(2-pyridinyl)benzyl]hydrazino}propylcarbamate;tert-butyl ((2S,3S)-3-hydroxy-1-phenyl-4-(1-(4-(pyridin-2-yl)benzyl)hydrazinyl)butan-2-yl)carbamate
• CAS NO: 857904-20-2
• Molecular Formula: C₂₇H₃₄N₄O₃
• Molecular Weight: 462.58386
• Mol File: 857904-20-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester(857904-20-2)
• EPA Substance Registry System: CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester(857904-20-2)

Safety Data

• Hazardous Substances Data: 857904-20-2(Hazardous Substances Data)

Usage

Description

CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester is a complex organic compound that serves as an intermediate in the synthesis of Atazanavir-d9, a deuterated analog of Atazanavir. Atazanavir is an azapeptide HIV protease inhibitor derivative, which has been investigated for its potential use in treating human immunodeficiency virus (HIV) and for anticancer purposes.

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, N-[(1S,2S)-2-hydroxy-1-(phenylMethyl)-3-[1-[[4-(2-pyridinyl)phenyl]Methyl]hydrazinyl]propyl]-, 1,1-diMethylethyl ester is used as an intermediate in the synthesis of Atazanavir-d9 for its potential application in treating human immunodeficiency virus (HIV) and for anticancer purposes. Its role in the synthesis process is crucial for the development of these therapeutic agents.

Upstream product

• 1313358-78-9 1-[4-(pyridin-2-yl)-phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1092540-12-9 C₂₇H₂₃N₃O₂ 
• 98760-08-8 (2R,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1,2-epoxy-4-phenylbutane 
• 198904-86-8 1-[4-(pyridine-2-yl)phenyl]-5(S)-2,5-bis[(tert-butyloxycarbonyl)amino]-4(S)-hydroxy-6-phenyl-2-azahexane 

Downstream Products

• 857904-21-3 Tert-butyl (1S,2S)-1-benzyl-2-hydroxy-3-{2-{(2S,3S)-2-[(methoxycarbonyl)amino]-3-methylpentanoyl}-1-[4-(2-pyridinyl)benzyl]hydrazino}propylcarbamate 
• 1092540-16-3 C₃₅H₃₅⁽²⁾H₁₂N₅O₆ 

Relevant articles and documents

Azapeptide derivatives as HIV protease inhibitors

This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.